STK33

Serine/threonine-protein kinase 33

2,213 patent compounds predicted against STK33, 1,577 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3847287	0.47	11/20
SCHEMBL3903906	0.47	10/20
SCHEMBL4826410	0.42	10/20
SCHEMBL1903147	0.42	10/20
SCHEMBL1905308	0.41	10/20
SCHEMBL1307817	0.44	9/20
SCHEMBL5507978	0.44	8/20
SCHEMBL1903037	0.44	8/20
SCHEMBL1904092	0.41	8/20
SCHEMBL1903735	0.41	8/20
SCHEMBL1898657	0.40	8/20
SCHEMBL3844820	0.47	7/20
SCHEMBL1901859	0.41	7/20
SCHEMBL1509112	0.57	6/20
SCHEMBL2135032	0.59	5/20
SCHEMBL4313704	0.52	5/20
SCHEMBL2740272	0.43	5/20
SCHEMBL693527	0.38	5/20
Pyrimidine (SCHEMBL3397113)	0.51	4/20
SCHEMBL1898900	0.47	4/20

Germline variants in STK33 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full STK33 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to STK33 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions	PHASE4	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	PHASE2	ACTIVE_NOT_RECRUITING
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.	PHASE2	ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma	PHASE2	ACTIVE_NOT_RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors	PHASE1	RECRUITING
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Biomarker Analysis of Gastrointestinal Cancer	nan	UNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a STK33 binder may also engage these)

Protein	Name	Similarity
Q0VD22	—	1.000	Q0VD22 →
Q924X7	—	1.000	Q924X7 →
SNRK	SNF-related serine/threonine-protein kinase	0.996	landscape →
Q0DCT8	—	0.996	Q0DCT8 →
Q66HD5	—	0.996	Q66HD5 →
Q66I46	—	0.995	Q66I46 →
A2QHV0	—	0.995	A2QHV0 →
Q9URY1	—	0.995	Q9URY1 →
A0A1D9QMS2	—	0.995	A0A1D9QMS2 →
A7A1P0	—	0.995	A7A1P0 →
E1B7X9	—	0.994	E1B7X9 →
Q63553	—	0.994	Q63553 →
Q6NTJ3	—	0.994	Q6NTJ3 →
F4I4F2	—	0.994	F4I4F2 →
Q9C813	—	0.994	Q9C813 →
Q9TTK0	—	0.994	Q9TTK0 →
Q09831	—	0.993	Q09831 →
B5VNQ3	—	0.993	B5VNQ3 →
Q9NLA1	—	0.993	Q9NLA1 →
Q39183	—	0.993	Q39183 →
P22204	—	0.993	P22204 →
Q9TU71	—	0.993	Q9TU71 →
F4JZ68	—	0.993	F4JZ68 →
Q4R7T5	—	0.993	Q4R7T5 →
P22517	—	0.993	P22517 →
A6QQR4	—	0.993	A6QQR4 →
Q7TNL3	—	0.993	Q7TNL3 →
Q19192	—	0.993	Q19192 →
Q12152	—	0.993	Q12152 →
NEK3	Serine/threonine-protein kinase Nek3	0.993	landscape →